The 3rd Cystic Fibrosis Clinical Trials Meeting: Advances in CF Clinical Trials

  • Navigating a rapidly changing landscape
  • Cystic fibrosis trials pipeline and national initiatives to support trials
  • How has COVID-19 changed trials
  • Unresolved issues for the post-modular era
  • Personalised medicine
  • What we have learned from the NIHR themed call
  • Reducing treatment burden for PWCF: CF STORM
  • The industry clinical interface: Identifying gaps and aligning strategies

Chiesi Limited is headquartered in Manchester and employs over 400 people. Based in Parma, Italy, Chiesi Farmaceutici is an international research-oriented group with over 80 years’ experience in the pharmaceutical sector, operating in 29 countries employing around 5,700 people. Chiesi researches, develops and markets innovative drugs for respiratory treatment, special care medicine and rare diseases.
The Group’s Research and Development Centre is also based in Parma and coordinates the activities of 6 other important R&D groups in France, the USA, the UK and Sweden to promote its own pre-clinical, clinical, and registration programmes. Chiesi is a certified Benefit Corporation (B Corp®) and is committed to operating in an environmentally responsible manner. Certified B Corps® meet the highest standards of verified social and environmental performance, transparency and accountability attempting to achieve the perfect balance between profit and sustainable objectives. For further information, please visit Chiesi's website.

AlgiPharma is a clinical stage biopharmaceutical company with a primary focus on respiratory diseases and other conditions caused by microbial infections and biofilms. The company's aim is to address unmet medical needs and fight diseases effectively through its innovative alginate technologies. Its alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance.

Sign up to our education events mailing list to be kept up to date with this and future events

Last updated: February 2021